TomoTherapy surges on FDA nod for radiation therapy technology
TomoTherapy Inc. (Nasdaq:TOMO) climbed nearly 9% this morning after announcing before the bell that it had received FDA approval for its TomoDirect radiation therapy technology.
TomoDirect was developed to complement TomoTherapy, the firm's advanced radiation therapy system for the treatment of a variety of cancers.
By mid-morning, Madison, Wisc.-based TomoTherapy is at $6.02, up $0.49 from Tuesday's close. The stock has traded between $4.63 and $26.80 during the past 52 weeks.
For detailed price information and news stories on TomoTherapy, click TOMO.
About the Author
Contributing author Mary Ann Azevedo has more than 13 years of writing and editing experience that includes coverage of a broad range of companies.
Read More
(click a star)
Enter comment: